SUPPLEMENTAL RESULTS

Table 1. Clinical and biochemical characteristics of FSGS patients classified according to age

Variables	Pediatric patients n=17	Adult patients n=62	**p**
Age [median (IQ 25-75)]. years	15 (13-16)	39 (33-55)	**0.000**
Creatinine [median (IQ 25-75)], mg/dl	1.07 (0.7-1.3)	1.1 (0.9-1.5)	0.436
GFR [median (IQ 25-75)] ml/min/1.73m2	102.5 (74.4-104.4)	85.8 (73.5-96.9)	0.176
Proteinuria [median (IQ 25-75)], g/dl	9.3 (7.1-13.5)	10.8 (8.5-14.4)	0.430
Albumin [median (IQ 25-75)], g/dl	2.2 (1.8-2.7)	2.49 (2.1-2.8)	0.886
Th1 [median (IQ 25-75)], %	23 (22-24.5)	23 (21-25.3)	1.000
TNFα [median (IQ 25-75)], pg/ml	10.4 (4.8-13.6)	8.8 (5.4-15.2)	0.208
IFNγ [median (IQ 25-75)], pg/ml	15.9 (8.8-22.6)	14.3 (5-25.4)	0.468
IL12 [median (IQ 25-75)], pg/ml	553 (317-726.3)	665 (544.5-777.7)	**0.030**
Th2 [median (IQ 25-75)], %	37 (32-49)	34 (31-39)	0.826
IL4 [median (IQ 25-75)], pg/ml	3.4 (1.8-4.7)	3.7 (2.4-6.8)	0.182
IL5 [median (IQ 25-75)], pg/ml	4.7 (2.3-5.3)	4.4 (2.2-7.1)	0.301
IL13 [median (IQ 25-75)], pg/ml	4.2 (3.1-8)	4.1 (2-6.4)	0.258
IgE [median (IQ 25-75)], g/dL	51 (46.5-51)	49 (46-102.3)	0.709
Th17 [median (IQ 25-75)], %	3.2 (2-15.1)	3.8 (2.6-24.6)	0.921
Th1 Th17 [median (IQ 25-75)], %	8 (4.4-10.8)	6 (3.9-9.8)	0.337
Treg [median (IQ 25-75)], %	2 (1.3-3.8)	2.1 (1.4-2.9)	**0.046**
IL17 [median (IQ 25-75)], pg/ml	7.8 (3-28.7)	6 (3.1-31.8)	0.388
IL23 [median (IQ 25-75)], pg/ml	32 (23-42.6)	41.8 (27.5-52.7)	0.490
sIL1R [median (IQ 25-75)], pg/ml	1425 (1058.3-2235.3)	2323.3 (1562-3215.6)	0.530
IL6 [median (IQ 25-75)], pg/ml	3.9 (1.6-12)	3.7 (1.8-13.9)	0.136
Hemopexin [median (IQ 25-75)], mg/ml	138 (56-334.5)	94 (49-326.4)	0.686
Haptoglobin [median (IQ 25-75)], mg/dl	246.8 (112.4-379.9)	134.8 (79.5-321.4)	0.645
suPAR [median (IQ 25-75)], ng/ml	3452 (2407.5-4571.5)	3405.9 (2457.1-4830)	0.484
uCD80 [median (IQ 25-75)], ng/mg creat	31 (22-46)	37.4 (16.3-58.1)	0.095

Table 2. Correlation matrix among biochemical variables in the whole group of patients.

	Age	Creat	GFR	Alb	Prot	ucD80	sIL1R	IL6	Hx	Hgl	IFNγ	TNFα	suPAR	IL12	IL17	IL23	IL4	IL13	IL5	IgE	Th1	Th2	Th1/Th17	Th17
Creat	0.36																							
GFR	-0.31**	-0.79**																						
Alb	-0.16	0.32**	-0.24*																					
Prot	0.31**	-0.19	0.17	0.36**																				
uCD80	0.04	-0.02	-0.08	0.09	-0.34**																			
sIL1R	0.3*	0.39**	-0.47**	0.06	-0.13	0.07																		
IL6	0.06	-0.01	0.04	-0.01	-0.13	0.11	0.23																	
Hx	-0.03	0.05	0.02	0.06	-0.15	0.26*	0.25	0.51**																
Hgl	-0.1	0.05	-0.03	-0.08	-0.1	0.36**	0.1	0.44**	0.61**															
IFN γ	-0.18	0.11	-0.03	0.25*	-0.21	0.01	0.14	0.03	0.09	0.03														
TNF α	-0.3	0.02	0.09	0.12	-0.1	0.09	0.13	0.2	0.61**	0.48**	0.17													
suPAR	0.26	-0.17	0.36	0.06	0.09	0.23*	-0.01	0.08	0.06	0.19	0.03	0.14												
IL12	0.09	-0.23*	0.03	-0.11	0.02	-0.02	0.02	-0.13	-0.32**	-0.29*	-0.05	-0.03	0.24*											
IL17	-0.11	0.08	-0.14	0.02	-0.08	-0.18	0.09	-0.25*	-0.38**	-0.42**	-0.07	-0.31**	0.01	0.47*										
IL23	0.2	-0.1	-0.07	-0.32**	0.14	-0.26*	-0.04	-0.09	-0.36**	-0.37**	-0.14	-0.34**	-0.19	0.62*	0.54**									
IL4	0.22	-0.07	0.01	-0.07	0.36**	-0.32**	-0.07	-0.15	-0.22*	-0.25*	-0.18	-0.31**	-0.08	-0.2	-0.25*	-0.03								
IL13	0.21	-0.1	-0.08	-0.16	0.21	-0.1	-0.22	-0.19	-0.25*	-0.23*	-0.27	-0.41**	0.04	-0.14	-0.16	0.02	0.6**							
IL5	0.17	-0.04	0.09	0.14	0.22	-0.09	-0.13	-0.13	-0.19	-0.15	0.14	-0.19	-0.17	-0.12	-0.31**	-0.1	0.3*	0.22*						
IgE	0.09	0.15	-0.11	0.09	0.14	-0.17	0.14	-0.06	0.16	0.11	-0.11	0.09	-0.13	-0.4**	-0.34**	-0.24*	0.4**	‘0.3**	0.3**					
Th1	-0.09	-0.19	0.09	-0.2	-0.07	0.43**	-0.16	0.03	0.16	0.35**	-0.09	0.19	0.06	-0.18	-0.29*	-0.29**	-0.14	-0.06	-0.2*	-0.19				
Th2	0.17	0.09	-0.07	0.01	0.23	-0.34**	-0.05	-0.14	-0.18	-0.19	-0.15	-0.27*	-0.16	-0.3**	-0.33**	-0.17	0,7**	0.6**	0.4**	-0.6**	-0.2*			
Th1/17	-0.09	-0.03	-0.07	-0.05	0.03	-0.19	0.14	-0.23*	-0.19	-0.22*	0.03	-0.15	0.04	0.46*	0.62**	0.39**	-0.21	-0.2	-0.3*	-0.3**	-0.2*	-0.3*		
Th17	-0.06	-0.03	-0.05	0.04	-0.06	-0.20	-0.01	-0.26*	-0.45**	-0.5**	-0.02	-0.35**	-0.03	0.5**	0.87**	0.53**	-0.16	-0.07	-0.18	-0.3*	-0,3*	-0.3**	0.5*	
Treg	-0.05	-0.14	0.09	-0.13	-0.04	0.23*	-0.16	0.24*	0.37**	0.42**	-0.08	0.21	-0.07	0.36*	0.64**	-0.41**	0,11	0.05	0.08	0.3*	0.21	0.2	-0.4*	-0.5

Creat: creatinine**; Alb:** albumine; **Prot:** proteïnúria; **GFR:** glomerular filtration rate; **sIL1r:** soluble IL1 receptor, **Hx:** hemopexin, **Hgl:** haptoglobin, **TNFα:** tumor necrosis factor alpha; **IFNγ:** interferón gamma, **suPAR:** soluble urokinase-type plasminogen activator receptor.

*p<0.05; **p<0.01

Table 3. Result of the ANOVA analysis comparing the three clusters of patients

	Mean Square	**F**	**P**
uCD80	4056,2	2,04	0,139
Age	125,6	0,545	0,583
Creatinine	0,3	1,291	0,283
Albumine	0,2	0,346	0,709
sIL1R	789126,3	0,458	0,635
IL6	328,9	3,771	0,029
IL12	430401,1	15,523	**0.000**
IL17	4269,5	33,791	**0.000**
IL23	2022,3	9,819	**0.000**
IL4	277,5	10,751	**0.000**
IL13	114	12,941	**0.000**
IL5	21,1	4,651	**0,013**
IgE	226346,1	6,714	**0,002**
TH1	28,8	11,524	**0,001**
TH2	1411	9,017	**0.000**
TH1TH17	222,5	5,387	**0,007**
TH17	2594,3	40,281	**0.000**
Tregs	15,1	22,612	**0.000**
SUPAR	6705720,7	3,97	**0,024**
Proteinuria	0,3	0,024	0,976
GFR	1012,9	2,713	0,074
Hx	72925	8,78	**0.000**
Hgl	14500,7	0,53	0,592
TNFα	101,1	2,738	0,073
IFNγ	37,9	0,442	0,645

GFR: glomerular filtration rate; **sIL1r:** soluble IL1 receptor, **Hx:** hemopexin, **Hgl:** haptoglobin, **TNFα:** tumor necrosis factor alpha; **IFNγ:** interferón gamma, **suPAR:** soluble urokinase-type plasminogen activator receptor.

Figure 1. Three-dimensional scatter-plot graphic representation of the distribution of patients according to their respective factor scores for the first three PCA, differentiating cortico-sensitive and cortico-resistant cases.



Cortico-sensitive patients are represented by blue cercles and cortico-resistant by red cercles.